Drug Trial News

RSS

Triglyceride-lowering drug can also decrease the risk of acute pancreatitis

Researchers from Mass General Brigham have found that olezarsen-a drug designed to lower triglyceride levels-can also decrease the risk of acute pancreatitis, a potential complication in patients with severely elevated triglyceride levels.

10 Nov 2025

Experimental intranasal vaccine triggers broad immune response against multiple strains of H5N1

Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 "bird flu".

6 Nov 2025

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton's tyrosine kinase inhibitors (BTKi).

6 Nov 2025

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome.

5 Nov 2025

Sertraline contributes to a modest improvement in core depression and anxiety symptoms

One of the most common antidepressants, sertraline, contributes to a modest improvement in core depression and anxiety symptoms, including low mood, within two weeks, finds a new analysis of a major clinical trial led by UCL researchers.

30 Oct 2025

WHO reviews highlight limited long-term data on GLP-1 drug safety

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.

30 Oct 2025

New drug can have a promising effect in cancer patients with active brain metastases

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of various tumor types.

28 Oct 2025

Semaglutide protects the heart beyond weight loss, SELECT trial shows

Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in people with overweight or obesity and cardiovascular disease. Early waist reduction explained only a third of this benefit, showing that semaglutide’s heart protection extends beyond fat loss.

26 Oct 2025

First multiple sclerosis patient in the UK receives CAR T cell therapy in groundbreaking trial

A multiple sclerosis (MS) patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a clinical trial testing whether this personalized treatment can slow or even halt the progression of the disease.

24 Oct 2025

Breakthrough combo therapy lowers death risk in recurrent prostate cancer

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

23 Oct 2025

Repeated ketamine infusions offer no extra benefit for people hospitalized with depression

Findings from a randomized and blinded clinical trial investigating repeated ketamine infusions for treating depression have revealed no extra benefit for ketamine when added onto standard care for people admitted to hospital for depression.

22 Oct 2025

Researchers highlight ethical implications of clinical trial terminations

The termination of thousands of federal grants that fund clinical trials threatens to reverse substantial progress in understanding and treating the health challenges of marginalized populations, particularly children and adolescents who are already underrepresented in research.

22 Oct 2025

$VT3989 shows promising antitumor activity in refractory mesothelioma patients$

VT3989 shows promising antitumor activity in refractory mesothelioma patients

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Largest trial of adjuvant pembrolizumab in Merkel cell carcinoma reports key benefit

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the risk of distant metastases for an aggressive form of skin cancer when given immediately after surgery, but did not significantly reduce the overall risk of recurrence, which was a co-primary endpoint of the trial.

21 Oct 2025

Novel combination therapy shows promise for advanced neuroendocrine tumors

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented this week at the European Society for Medical Oncology (ESMO) Congress 2025.

21 Oct 2025

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

18 Oct 2025

Oral combination regimen improves survival in ER-positive HER-2-negative breast cancer

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.

18 Oct 2025

Targeted therapy combination shows superior outcomes in advanced kidney cancer

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.

18 Oct 2025

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.

17 Oct 2025

Drug Trial News

Triglyceride-lowering drug can also decrease the risk of acute pancreatitis

Experimental intranasal vaccine triggers broad immune response against multiple strains of H5N1

Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

Sertraline contributes to a modest improvement in core depression and anxiety symptoms

WHO reviews highlight limited long-term data on GLP-1 drug safety

New drug can have a promising effect in cancer patients with active brain metastases

Semaglutide protects the heart beyond weight loss, SELECT trial shows

First multiple sclerosis patient in the UK receives CAR T cell therapy in groundbreaking trial

Breakthrough combo therapy lowers death risk in recurrent prostate cancer

Repeated ketamine infusions offer no extra benefit for people hospitalized with depression

Researchers highlight ethical implications of clinical trial terminations

VT3989 shows promising antitumor activity in refractory mesothelioma patients

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

Largest trial of adjuvant pembrolizumab in Merkel cell carcinoma reports key benefit

Novel combination therapy shows promise for advanced neuroendocrine tumors

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

Oral combination regimen improves survival in ER-positive HER-2-negative breast cancer

Targeted therapy combination shows superior outcomes in advanced kidney cancer

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News